Woodmont Investment Counsel LLC Acquires 4,041 Shares of Johnson & Johnson (NYSE:JNJ)

Woodmont Investment Counsel LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 89,712 shares of the company's stock after buying an additional 4,041 shares during the quarter. Johnson & Johnson makes up 1.0% of Woodmont Investment Counsel LLC's holdings, making the stock its 25th biggest holding. Woodmont Investment Counsel LLC's holdings in Johnson & Johnson were worth $12,974,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of JNJ. IFS Advisors LLC grew its stake in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $29,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $32,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson during the third quarter worth about $35,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $38,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the subject of several analyst reports. Bank of America raised their price target on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a report on Wednesday, March 5th. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Stifel Nicolaus decreased their price target on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Argus raised Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Finally, Raymond James lowered their target price on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $171.33.

Remove Ads

Johnson & Johnson Stock Down 1.3 %

Shares of NYSE:JNJ traded down $2.15 during mid-day trading on Tuesday, hitting $161.14. 7,455,254 shares of the company traded hands, compared to its average volume of 7,088,162. The stock has a 50-day moving average price of $157.37 and a two-hundred day moving average price of $156.16. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The stock has a market cap of $388.32 billion, a P/E ratio of 24.23, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the business posted $2.29 EPS. The business's revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's payout ratio is 74.59%.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.